Search for a trial

Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for Treatment of In-Stent Restenosis in the Superficial Femoral Artery.

To evaluate the post-market performance of the GORE® VIABAHN® Endoprosthesis for the treatment of in-stent restenosis in the superficial femoral artery.

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, 2-PERIOD, CROSSOVER STUDY TO COMPARE THE EFFECTS OF EZETIMIBE/SIMVASTATIN (10 MG/10 MG) COMBINATION TABLET VERSUS SIMVASTATIN 80 MG TABLET ON POSTPRANDIAL ARTERIAL ENDOTHELIAL FUNCTION IN PATIENTS WITH METABOLIC SYNDROME

The combination of simvastatin 10 mg/ezetimibe 10 mg has a beneficial effect on post prandial endothelial function in comparison to monotherapy with simvastatin 80 mg.

The ENDURRANCE-1 Study. ;Exploring durable remission with rituximab in ANCA associated vasculitis

This study has been transitioned to CTIS with ID 2023-507868-39-00 check the CTIS register for the current data. In this randomized study the primary objective is to demonstrate a clinical significant reduction of RTX retreatments in AAV patients…

Reversal Of Arterial Disease by modulating Magnesium And Phosphate

Primary Objective:- Determine the effect of 24 weeks of oral magnesium supplementation and/or the phosphate binder sucroferric oxyhydroxide on arterial wall stiffness in CKD patients, as measured by pulse wave velocity.Secondary Objectives:-…

A randomized controlled trial comparing venous stenting with conservative treatment in patients with Deep Venous Obstruction

Primary Objective: Measure QoL (VEINES QoL/Sym) change in patients with DVO at one year after PTA and stenting compared to conventional therapy (short class II elastic compressions stockings, exercise, lymph drainage therapy and the use of (pain)…

A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus (Harmony Outcomes Trial, GLP116174)

Primary: Time to first occurrence of MACE (cardiovascular death, myocardial infarction, or stroke) [Non-inferiority].Secondary: Time to first occurrence of MACE [Superiority], MACE or urgent revascularization for unstable angina, individual…

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk

The primary objective of the study is to evaluate neurocognitive function with use of Praluent after 96 weeks of treatment versus placebo.